LEDGINs, non-catalytic site inhibitors of HIV-1 integrase: a patent review (2006 – 2014)
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Integration of the viral genome into the host cell chromatin is a central step in the replication cycle of the HIV. Blocking the viral integrase (IN) enzyme therefore provides an attractive therapeutic strategy, as evidenced by the recent clinical approval of three IN strand transfer inhibitors. Viral resistance and cross-resistance among these inhibitors, however, warrant the search for compounds targeting HIV integration through alternative mechanisms of action. AREAS COVERED: The most potent class of allosteric IN inhibitors was independently identified at the University of Leuven, Belgium, and at Boehringer Ingelheim, Canada. These compounds, coined LEDGINs (after the lens epithelium-derived growth factor/p75 cofactor binding pocket on IN) or non-catalytic site IN inhibitors (NCINIs) by the respective groups, have shown remarkable antiviral activity. This review provides a brief introduction to the compound class and discusses the recent patent literature (2006 to the present). EXPERT OPINION: LEDGINs are still early in development. Trials with clinical candidate BI-224436 were put on hold despite promising results. Literature, however, reveals that almost all major pharmaceutical companies active in the treatment of HIV/AIDS have taken a significant interest in this class. As a result, several of these inhibitors may soon enter clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells
Hazuda, D. J., Felock, P., Witmer, M., Wolfe, A., Stillmock, K., Grobler, J. A., Espeseth, A., Gabryelski, L., Schleif, W., Blau, C., et al. (2000) · Science · doi:10.1126/science.287.5453.646 · Cited by 1,131 · cited 1×
“These compounds are integrase catalytic site inhibitors that specifically inhibit the strand transfer step [14].”
BackgroundHIV-1 Integrase Forms Stable Tetramers and Associates with LEDGF/p75 Protein in Human Cells
Cherepanov, P., Maertens, G., Proost, P., Devreese, B., Van Beeumen, J., Engelborghs, Y., De Clercq, E., & Debyser, Z. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209278200 · Cited by 704 · cited 1×
“Additionally, LEDGF/p75 was shown to protect IN from proteolytic degradation, modulate IN oligomerization and stimulate its catalytic activity [37-40].”
BackgroundSelf-citationRetroviral intasome assembly and inhibition of DNA strand transfer
Hare, S., Gupta, S. S., Valkov, E., Engelman, A., & Cherepanov, P. (2010) · Nature · doi:10.1038/nature08784 · Cited by 678 · cited 1×
“succeeded in crystallizing the related prototype foamy virus IN ( genus Spumavirinae) in a functional complex with synthetic long terminal repeat (LTR) DNA ends, known as the intasome [10].”
BackgroundA role for LEDGF/p75 in targeting HIV DNA integration
Ciuffi, A., Llano, M., Poeschla, E., Hoffmann, C., Leipzig, J., Shinn, P., Ecker, J. R., & Bushman, F. (2005) · Nature Medicine · doi:10.1038/nm1329 · Cited by 658 · cited 1×
“During HIV replication, LEDGF/p75 specifically tethers and targets the pre-integration complex (PIC) to the bodies of active genes [30,35,36].”
BackgroundAn essential role for LEDGF/p75 in HIV integration
Llano, M., Saenz, D. T., Meehan, A., Wongthida, P., Peretz, M., Walker, W. H., Teo, W., & Poeschla, E. M. (2006) · Science · doi:10.1126/science.1132319 · Cited by 537
LEDGF/p75 Is Essential for Nuclear and Chromosomal Targeting of HIV-1 Integrase in Human Cells
Maertens, G., Cherepanov, P., Pluymers, W., Busschots, K., De Clercq, E., Debyser, Z., & Engelborghs, Y. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303594200 · Cited by 493 · cited 1×
“Additionally, LEDGF/p75 was shown to protect IN from proteolytic degradation, modulate IN oligomerization and stimulate its catalytic activity [37-40].”
BackgroundSelf-citationChrist, F., Voet, A., Marchand, A., Nicolet, S., Desimmie, B. A., Marchand, D., Bardiot, D., Van der Veken, N. J., Van Remoortel, B., Strelkov, S. V., et al. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.370 · Cited by 479
Self-citationShun, M.-C., Raghavendra, N. K., Vandegraaff, N., Daigle, J. E., Hughes, S., Kellam, P., Cherepanov, P., & Engelman, A. (2007) · Genes & Development · doi:10.1101/gad.1565107 · Cited by 467 · cited 1×
“During HIV replication, LEDGF/p75 specifically tethers and targets the pre-integration complex (PIC) to the bodies of active genes [30,35,36].”
BackgroundMultiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication
Engelman, A., Englund, G., Orenstein, J. M., Martin, M. A., & Craigie, R. (1995) · Journal of Virology · doi:10.1128/jvi.69.5.2729-2736.1995 · Cited by 445
Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75
Cherepanov, P., Ambrosio, A. L. B., Rahman, S., Ellenberger, T., & Engelman, A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506924102 · Cited by 408
Cherepanov, P., Devroe, E., Silver, P. A., & Engelman, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406307200 · Cited by 287
Solution structure of the HIV-1 integrase-binding domain in LEDGF/p75
Cherepanov, P., Sun, Z.-Y. J., Rahman, S., Maertens, G., Wagner, G., & Engelman, A. (2005) · Nature Structural & Molecular Biology · doi:10.1038/nsmb937 · Cited by 235 · cited 2×
“Finally, solution of the LEDGF/ p75 IBD--HIV-1 IN CCD co-crystal structure [31,46] plus the observation that IBD-derived peptides also modulate IN oligomerization and block IN catalytic activity [47] further spurred on research efforts to develop a small molecule inhibitor of the IN -- LEDGF/p75 interaction [48-53].”
BackgroundStructural basis for high-affinity binding of LEDGF PWWP to mononucleosomes
Eidahl, J. O., Crowe, B. L., North, J. A., McKee, C. J., Shkriabai, N., Feng, L., Plumb, M., Graham, R. L., Gorelick, R. J., Hess, S., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt074 · Cited by 207
Jurado, K. A., Wang, H., Slaughter, A., Feng, L., Kessl, J. J., Koh, Y., Wang, W., Ballandras-Colas, A., Patel, P. A., Fuchs, J. R., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300703110 · Cited by 203
Llano, M., Vanegas, M., Hutchins, N., Thompson, D., Delgado, S., & Poeschla, E. M. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.04.073 · Cited by 199
Retroviral integrase superfamily: the structural perspective
Nowotny, M. (2009) · The EMBO Reports · doi:10.1038/embor.2008.256 · Cited by 183 · cited 1×
“While they are all essential for the biological activity of IN, it is the CCD that harbors the catalytic triad [9].”
BackgroundDiscovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1
Fader, L. D., Malenfant, E., Parisien, M., Carson, R., Bilodeau, F., Landry, S., Pesant, M., Brochu, C., Morin, S., Chabot, C., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500002n · Cited by 178
New Class of HIV-1 Integrase (IN) Inhibitors with a Dual Mode of Action
Tsiang, M., Jones, G. S., Niedziela-Majka, A., Kan, E., Lansdon, E. B., Huang, W., Hung, M., Samuel, D., Novikov, N., Xu, Y., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.347534 · Cited by 167 · cited 10×
“Although a consensus has yet to be reached on the precise extent of their relative contributions, both effects may contribute to inhibition of HIV-1 replication [23,54,58,111].”
BackgroundInfluentialLEDGINs inhibit late stage HIV-1 replication by modulating integrase multimerization in the virions
Desimmie, B. A., Schrijvers, R., Demeulemeester, J., Borrenberghs, D., Weydert, C., Thys, W., Vets, S., Van Remoortel, B., Hofkens, J., De Rijck, J., et al. (2013) · Retrovirology · doi:10.1186/1742-4690-10-57 · Cited by 139 · cited 7×
“Possibly due to this reduced competition, LEDGIN potency at the late stage may be higher than at the early stage [106,115,116] and the overall potency of LEDGINs in multiple round Upright view Lateral view”
BackgroundInfluentialSelf-citationLe Rouzic, E., Bonnard, D., Chasset, S., Bruneau, J.-M., Chevreuil, F., Le Strat, F., Nguyen, J., Beauvoir, R., Amadori, C., Brias, J., et al. (2013) · Retrovirology · doi:10.1186/1742-4690-10-144 · Cited by 127
Balakrishnan, M., Yant, S. R., Tsai, L., O’Sullivan, C., Bam, R. A., Tsai, A., Niedziela-Majka, A., Stray, K. M., Sakowicz, R., & Cihlar, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074163 · Cited by 126 · cited 7×
“Possibly due to this reduced competition, LEDGIN potency at the late stage may be higher than at the early stage [106,115,116] and the overall potency of LEDGINs in multiple round Upright view Lateral view”
BackgroundInfluentialPreclinical Profile of BI 224436, a Novel HIV-1 Non-Catalytic-Site Integrase Inhibitor
Fenwick, C., Amad, M., Bailey, M. D., Bethell, R., Bös, M., Bonneau, P., Cordingley, M., Coulombe, R., Duan, J., Edwards, P., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02719-13 · Cited by 99 · cited 10×
“Second-generation INSTIs such as dolutegravir have a higher genetic barrier toward resistance, but close monitoring of Expert Opin.”
BackgroundInfluential
Cited by
Vranckx, L. S., Demeulemeester, J., Saleh, S., Boll, A., Vansant, G., Schrijvers, R., Weydert, C., Battivelli, E., Verdin, E., Cereseto, A., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.04.039 · Cited by 113
“IN interaction and HIV integration (Christ et al., 2010; Demeulemeester et al., 2014a), on the HIV reservoir in cell culture.”
BackgroundInfluentialSelf-citationMultiple cellular proteins interact with LEDGF/p75 through a conserved unstructured consensus motif
Tesina, P., Čermáková, K., Hořejší, M., Procházková, K., Fábry, M., Sharma, S., Christ, F., Demeulemeester, J., Debyser, Z., Rijck, J. D., et al. (2015) · Nature Communications · doi:10.1038/ncomms8968 · Cited by 74
Self-citationHIV-1 integrase tetramers are the antiviral target of pyridine-based allosteric integrase inhibitors
Koneru, P. C., Francis, A. C., Deng, N., Rebensburg, S. V., Hoyte, A. C., Lindenberger, J., Adu-Ampratwum, D., Larue, R. C., Wempe, M. F., Engelman, A. N., et al. (2019) · eLife · doi:10.7554/elife.46344 · Cited by 49
“, 2014b) (Figure 1A); ii) other studies successfully explored different core ring structures (Demeulemeester et al., 2014; Fader et al., 2016; Patel et al., 2016a; Patel et al., 2016b; Sharma et al., 2014) to also synthesize highly potent ALLINIs.”
BackgroundBonnard, D., Le Rouzic, E., Eiler, S., Amadori, C., Orlov, I., Bruneau, J.-M., Brias, J., Barbion, J., Chevreuil, F., Spehner, D., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.816793 · Cited by 42
Peese, K. M., Allard, C. W., Connolly, T., Johnson, B. L., Li, C., Patel, M., Sorensen, M. E., Walker, M. A., Meanwell, N. A., McAuliffe, B., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01473 · Cited by 39
Metadata
- Authors
- Demeulemeester, J., Chaltin, P., Marchand, A., De Maeyer, M., Debyser, Z., & Christ, F.
- Venue
- Expert Opinion on Therapeutic Patents
- Publisher
- Informa UK Limited
- Published
- 2014-03-25
- Volume
- 24
- Issue
- 6
- Pages
- 609-632
- ISSN
- 1354-3776 (ISSN-L)
- 1744-7674
- OpenAlex
- W1969081293
- Cited by
- 83
- References
- 22
- FWCI
- 6.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.